Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension by Grünig, Ekkehard et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Clinical Investigations 
 Respiration 2011;81:394–401 
 DOI: 10.1159/000322475 
 Effect of Exercise and Respiratory Training on 
Clinical Progression and Survival in Patients with 
Severe Chronic Pulmonary Hypertension 
 Ekkehard Grünig  a    Nicola Ehlken  a    Ardeschir Ghofrani  f    Gerd Staehler  d    
F. Joachim Meyer  b    Jana Juenger  c    Christian F. Opitz  i    Hans Klose  g    
Heinrike Wilkens  h    Stephan Rosenkranz  j    Horst Olschewski  k    Michael Halank  e 
 a   Center for Pulmonary Hypertension, Thoracic Clinic, and Departments of  b   Cardiology and  c   Psychosomatic 
Medicine, University of Heidelberg,  Heidelberg , Departments of Pneumology,  d   Clinic Löwenstein,  Löwenstein , and 
Universities of  e   Dresden ,  f   Giessen ,  g   Hamburg and  h   Homburg , and Departments of Cardiology,  i   DRK Kliniken Berlin 
Köpenick,  Berlin , and  j   University of Cologne,  Köln , Germany;  k   Division of Pulmonology, Medical University Graz, 
 Graz , Austria 
training well without severe adverse events. In week 15, 
6-min walking test results were significantly improved com-
pared to baseline (by 84  8 49 m, p  ! 0.001), as well as QoL 
scores, WHO functional class (from 2.9  8 0.5 to 2.6  8 0.6,
p  ! 0.01), peak oxygen consumption (from 12.5  8 3.0 to 14.6 
 8 3.9 ml/min/kg, p  ! 0.001), heart rate at rest (from 75  8 12 
to 61  8 18 beats/min, p  ! 0.001) and maximal workload 
(from 65  8 21 to 80  8 25 W, p  ! 0.001). Survival at 1 and 2 
years was 100 and 95%, respectively. Fifteen events occurred 
during the follow-up.  Conclusion: This study indicates that 
exercise and respiratory training as add-on to medical treat-
ment may improve exercise capacity and QoL, and that they 
have a good long-term safety in the described setting. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Chronic pulmonary hypertension (PH) is associated 
with impaired exercise capacity, quality of life (QoL) and 
survival  [1, 2] . Within the last decade, new disease-target-
ed medical therapies have been approved for treatment of 
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 Abstract 
 Background: Even though specific agents for the treatment 
of patients with pulmonary hypertension (PH) are available, 
in PH patients, physical capacity and quality of life (QoL) are 
often restricted and survival is reduced.  Objectives: This 
study prospectively investigated the long-term effects of re-
spiratory and exercise training in patients with severe chron-
ic PH regarding safety, time to clinical worsening and sur-
vival.  Methods: Fifty-eight consecutive patients with severe 
PH on stable disease-targeted medication received exercise 
and respiratory training in hospital for 3 weeks and contin-
ued at home. They were prospectively followed for 24  8 12 
months. Primary endpoints were time to clinical worsening 
and survival. Adverse events and changes in the 6-min walk-
ing test, QoL, WHO functional class and gas exchange were 
secondary endpoints and were evaluated at baseline and at 
weeks 3 and 15.  Results: All patients tolerated the exercise 
 Received: March 25, 2010 
 Accepted after revision: November 2, 2010 
 Published online: February 9, 2011 
 Ekkehard Grünig, MD 
 Center for Pulmonary Hypertension, Thoracic Clinic ,  University Hospital Heidelberg 
 Amalienstrasse 5, DE–69126 Heidelberg 
 Tel. +49 6221 396 8053, Fax +49 6221 396 1209
E-Mail ekkehard.gruenig   @   thoraxklinik-heidelberg.de 
 © 2011 S. Karger AG, Basel
0025–7931/11/0815–0394$38.00/0 
 Accessible online at:
www.karger.com/res 
 Effect of Exercise and Respiratory 
Training on PH 
Respiration 2011;81:394–401 395
pulmonary arterial hypertension (PAH), such as intrave-
nous epoprostenol, inhaled iloprost, subcutaneously and 
intravenously administered treprostinil, the endothelin-
receptor antagonists bosentan, sitaxsentan and ambris-
entan, and the phosphodiesterase type 5 inhibitors silde-
nafil and tadalafil  [3–5] . Combinations of these agents 
have been shown to further improve symptoms, exercise 
capacity and QoL in PAH patients  [6–9] . However, de-
spite optimized medical therapy patients are still far from 
their normal exercise capacity and survival rate, with an 
annual mortality rate of approximately 5–10%  [10–14] or 
even higher  [10] . In patients with non-idiopathic forms of 
PAH, the outcome of disease has been less well character-
ized. Long-term effects of novel medical therapies are still 
unknown. The only prospective, randomized trials to 
demonstrate a favorable impact on mortality in PAH pa-
tients have been performed using continuous intravenous 
epoprostenol [11]. The distance walked in 6 min  [15] and 
QoL  [16] represent surrogate markers of survival since 
they are strongly, independently associated with mortal-
ity in PAH patients. In a recent study, we have demon-
strated that carefully monitored exercise and respiratory 
training as add-on to optimized medical therapy improve 
the 6-min walking distance and QoL in patients with 
 severe PH  [17] . Exercise capacity, peak oxygen uptake, 
workload at anaerobic threshold, maximum heart rate 
and systolic pulmonary artery pressure at rest improved 
as well, indicating a reduction in right ventricular work 
 [17] . The increase in the 6-min walking distance follow-
ing 15 weeks of exercise training was 96  8 61 m, being 
greater than that achieved with PH-specific medical ther-
apy  [17] . Exercise training in PH has also been shown
to improve exercise endurance and quadriceps muscle 
strength  [18] .
 However, although these previous studies  [17, 18] in a 
limited number of patients may indicate that exercise and 
respiratory training are useful adjunctive therapies to PH 
 [19] , so far no data in a larger patient cohort or long-term 
data are available. In progressive disease, exercise train-
ing may even reduce survival, as seen in a recent study of 
exercise training in monocrotaline-induced PH in rats 
 [20] . Therefore, the aim of this prospective study was to 
evaluate whether the positive effects of exercise training 
on physical capacity and QoL can be repeated in a larger 
patient cohort, and whether an exercise program is safe 
in the long term, results in persistent improvement in car-
diopulmonary function or at least does not reduce sur-
vival or time to clinical worsening.
 Patients and Methods 
 Study Population and Design  
 This prospective study investigated consecutive patients with 
severe chronic PH and right heart failure between January 2003 
and April 2007 (inclusion and follow-up time) who received ex-
ercise and respiratory training as add-on to disease-targeted 
medication. Further inclusion criteria were age between 18 and 
80 years and World Health Organization (WHO) functional class 
II–IV. Patients had to be stable and compensated with optimized 
medical therapy (endothelin antagonists, iloprost, sildenafil, an-
ticoagulants, diuretics and supplemental oxygen) for at least 3 
months before entering the study. The diagnosis was established 
at the participating PH centers according to current guidelines  [1, 
3] . All patients underwent a detailed clinical workup including 
right heart catheterization. Testing for vasoreactivity and left 
heart catheterization were performed when clinically indicated. 
Sixty-one patients were included in the study; 3 had to be exclud-
ed due to the following reasons: in 1 ‘PAH’ patient, echocardiog-
raphy at baseline revealed severe atypical mitral stenosis, and 
pulmonary hemodynamics improved after cardiac surgery; 1 pa-
tient discontinued due to familial reasons, and 1 patient had to 
adjust PH-specific medication 1 week before he was scheduled for 
the training program. Thus, the final training group consisted of 
58 consecutive patients who were prospectively followed for 24  8 
12 months. The patients had been referred from 9 centers. They 
were assessed clinically at baseline and 3 and 15 weeks after the 
start of exercise training and followed thereafter by regular clin-
ical visits and/or phone contact for 24  8 12 months ( fig. 1 ). All 
patients gave written informed consent for this study, which was 
approved by the Ethics Committee of the University of Heidel-
berg.
 Methods 
 Efficacy parameters were prospectively evaluated at baseline 
and after 3 and 15 weeks, as described previously  [17] . The 6-min 
walking test (6MWT) was carried out in a large hall under stan-
dardized conditions  [21] . Health-related QoL assessment was per-
formed by the Short-Form Health Survey (SF-36)  [22] . The results 
of the SF-36 questionnaire obtained at baseline were compared to 
those obtained after 15 weeks. 6MWT, SF-36 and other efficacy 
parameters were assessed by investigators who were blinded to the 
clinical data of the patients. Changes in WHO functional classi-
fication, Borg dyspnea index (with 6 representing no exertion and 
20 maximal exertion)  [23] and gas exchange were also analyzed 
 [24] . Cardiopulmonary exercise testing was carried out during 
supine bicycle exercise, as described previously  [17] . Workload, 
heart rate, ventilation (V E ), oxygen uptake (V O 2 ) and carbon di-
oxide output (V CO 2 ) were measured continuously. The anaerobic 
threshold was detected with the V-slope method  [24] . Further fol-
low-up with evaluation of safety, survival and predefined events 
indicating clinical worsening was performed by regular control 
assessments within the participating centers, phone interview 
and review of the patients’ clinical records.
 Exercise Training Program 
 Exercises and respiratory training were performed as de-
scribed before  [17] and started in the Koenigstuhl Clinic in Hei-
delberg within the first 3 weeks of rehabilitation. The program 
consisted of daily interval bicycle ergometer training at low 
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workloads as well as walking, dumbbell training of single muscle 
groups using low weights (500–1,000 g) and respiratory training 
(5 days/week). Furthermore, mental training to improve the pa-
tients’ perception of their individual physical abilities and limits 
was performed. The program was closely supervised by physical 
therapists and physicians, as described before  [17] . Oxygen satu-
ration and heart rate were monitored continuously throughout 
the training and were used to adjust the training intensity. When 
patients’ oxygen saturation fell below 85% with exercise, they re-
ceived supplemental oxygen (3–6 l/min) during the training. 
Twenty-one patients who were already on oxygen therapy (16–
24 h/day) prior to inclusion into this study remained on oxygen 
throughout the training program. At discharge from the hospital 
after 3 weeks, patients of the training group received an individ-
ualized training manual and ordered a bicycle ergometer for use 
at home. The amount of training at home was supervised by 
phone every 2–4 weeks by physiotherapists and/or physicians. 
During the home-based respiratory and exercise training, all pa-
tients were asked to keep close contact to the physicians of the 
training program and to their general practitioners and special-
ized center.
 Statistical Methods 
 Data are given as means  8 SD. Intragroup comparisons (base-
line vs. 3 and 15 weeks) were conducted by a paired, two-sided 
Student’s t test for 6MWT, workload, gas exchange and heart rate. 
WHO functional class and Borg dyspnea index were analyzed by 
Wilcoxon’s rank test. Total scores and subscores of the SF-36 ques-
tionnaire were compared by ANOVA and two-tailed Student’s t 
test. p  ! 0.05 was considered statistically significant. Bonferroni 
Index patients of the prospective study (n = 61)
with severe chronic PH; NYHA functional class II–IV; clinically stable under optimized
medical therapy (11 centers)
Excluded: n = 3
Training group (n = 58)
included January 2003 to April 2007
Examination at baseline
Examination after 3 weeks
Rehabilitation program
3 weeks in hospital with
exercise and respiratory training
Continuation of
training at home
Examination after 15 weeks
Prospective
follow-up
24 ± 12 months
by phone
and control
assessments
within the centers
Training group (n = 58)
1 died due to PAH
1 died due to colon carcinoma
1 lung transplantation
15 events
 Fig. 1. Study population and design: from 
January 2003 to April 2007, 61 patients 
with severe chronic PH were consecutively 
included in the training group. Three of 
the 61 patients had to be excluded, 58
were prospectively followed for 24  8 12 
months. 
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adjustment for multiple comparisons was performed for 6-min 
walking distances and QoL parameters.
 Survival and time to clinical worsening (event-free survival) 
were estimated by the Kaplan-Meier method using a stratified 
log-rank test for group comparisons. The start of rehabilitation 
was used as the index date for determining survival or time to 
clinical worsening. Clinical worsening was defined as combined 
endpoint of PH-related death, lung transplantation, hospitaliza-
tion for PH, clinical worsening leading to initiation of new chron-
ic PH-specific treatment or combined WHO functional classifica-
tion deterioration and a  6 15% decrease in 6MWT from baseline. 
Patients who had no clinical worsening event were censored at 
their last follow-up date.
 Results 
 Study Population  
 Demographic data, diagnosis, functional class, 6-min 
walking distance, hemodynamic values and medical 
therapy are summarized in  table 1 . Combination thera-
pies, including two or three PH-specific agents, were used 
in 35% of the patients. Most patients (83%) were in NYHA 
class III at baseline, with a mean cardiac index of 2.2  8 
0.7 l/min/m 2 , indicating a severe form of disease. With 
respect to the 6-min walking distance at baseline, it has 
to be kept in mind that this test was performed in a large 
hall of the rehabilitation clinic Koenigstuhl. All patients 
had significantly lower 6-min walking distances when 
measured in their PAH center. Most patients suffered 
from PAH associated with a variety of conditions ( ta-
ble 1 ).
 Assessment of Training Effects in the Prospectively 
Followed Training Group 
 Compared to baseline, mean 6-min walking distance 
increased significantly after 3 (78  8 44 m) and 15 weeks 
(84  8 49 m, p  ! 0.001;  table 2 ). All patients reported a 
noticeable improvement in their symptoms. Mean WHO 
functional class improved significantly from 2.9  8 0.5 to 
2.6  8 0.6 after 15 weeks ( table 2 ). Mean peak oxygen con-
sumption, peak oxygen uptake in percent of the predicted 
value and mean V  E max increased significantly from base-
line to weeks 3 and 15. The Borg scale remained un-
changed, although higher workloads and higher heart 
rates were attained during exercise ( table 2 ). Exercise and 
respiratory training significantly reduced heart rate at 
rest and improved QoL parameters, as indicated by the 
subscale scores for physical functioning (p = 0.018), role 
physical (p = 0.003), general health perception (p  ! 0.05), 
vitality (p = 0.001), social functioning (p = 0.002), role 
emotional (p = 0.014) and mental health (p = 0.017;  ta-
ble 2 ). Using Bonferroni adjustment, p values below 0.016 
(6MWT) and 0.005 (SF-36) remained statistically signif-
icant.
 Outcome 
 Overall, 2 of 58 patients of the training group (3.4%) 
died during the observation period. One patient died 
from right heart failure and the other patient died from 
metastatic colon carcinoma. The probability of survival 
was 100 and 95% at 1 and 2 years, respectively ( fig. 2 ). On 
admission to the exercise training program, 3 of the 58 
patients had been listed for lung transplantation. One 
 patient improved markedly and was removed from the 
Table 1. D emographics and baseline characteristics
Characteristics Training 
group
Patients, n 58
Females/males 42/16
Age, years 51812
Height, cm 16889
Weight, kg 72812
WHO functional class, n
I 0
II 10
III 44
IV 4
Combination therapy
Monotherapy 38
Dual therapy 18
Triple therapy 2
Cause of PH, n
PAH
Idiopathic PAH 37
Familial PAH 3
PAH associated with
Collagen vascular disease 2
Congenital systemic to pulmonary shunts 1
Portal hypertension 3
HIV 1
PH associated with
Chronic obstructive pulmonary disease 1
Interstitial lung disease 2
CTEPH 6
Others 2
Walking distance at 6 min, m 440890
Cardiac catheterization
Mean PAP, mm Hg 51815
PVR, dynscm–5 8548367
Cardiac index, l/min/m2 2.280.7
V alues are means 8 SD. CTEPH = Chronic thromboembolic 
PH; PAP = pulmonary artery pressure; PVR = pulmonary vascu-
lar resistance.
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Table 2. E fficacy parameters of the training group
Characteristics Baseline After 3 weeks After 15 weeks
6-min walking distance, m 440890 518893*** 527874***
WHO class 2.980.5 2.780.5*** 2.680.6**
Cardiopulmonary exercise testing
Peak VO2, ml/min/kg 12.583.0 14.083.6*** 14.683.9***
VO2, % predicted 51813 60819*** 59815***
VEmax, l/min 43813 50816*** 51816***
Workload at AT, W 49817 54819** 61822***
VO2 at AT, ml/min 7748207 8748246*** 8848252***
EqCO2 at AT 48812 47812 46812
HR at rest, min–1 75812 75813 61818***
HRmax, min–1 121819 127821*** 131819***
Borg 1682 1582 1582
Workload, W 65821 76826*** 80825***
SF-36
Physical functioning 38.9820.7 52.8821.1***
Role physical 30.0838.0 53.4840.2***
General health 40.6816.4 45.6818.3*
Vitality 47.1817.6 57.3818.4***
Social functioning 68.3824.2 78.8823.6**
Role emotional 68.2844.2 80.1832.5*
Mental health 64.5821.4 72.6815.2***
A T = Anaerobic threshold; HR = heart rate. * p < 0.05, ** p < 0.01, *** p < 0.001, vs. baseline.
0
S
u
rv
iv
a
l
Patients at
risk (n)
0.2
0.4
0.6
0.8
1.0
0 6 12 18 24 30 36 42 48
Time (months)
58 36 27 20 12 4 1
 Fig. 2. Survival in the 58 patients of the training group. Kaplan-
Meier curves of survival in patients (n) with severe PH (function-
al class III–IV) under optimized medical treatment receiving re-
spiratory and exercise training. + indicates censored cases, log-
rank test: p  ! 0.05. 
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 Fig. 3. Time to clinical worsening in the training group. Kaplan-
Meier estimates of time to clinical worsening (event-free survival) 
of patients with exercise training. + indicates censored cases, log-
rank test: p  ! 0.05. 
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transplantation list, 1 remained stable until the end of 
follow-up, and 1 required lung transplantation 18 months 
later because of clinical worsening.
 Time to Clinical Worsening 
 During the follow-up, 15 events occurred ( fig. 3 ;  ta-
ble 3 ): 9 patients received new chronic PH treatment due 
to clinical worsening, 3 patients had a deterioration in 
functional class and 6-min walking distance, 1 patient 
required in-hospital treatment, 1 patient underwent lung 
transplantation and 1 patient died.
 Safety 
 Exercise training was well tolerated by all patients, and 
there were no severe adverse events such as progression 
of symptoms, syncope or worsening of right heart failure 
during the in-hospital program. Two patients experi-
enced a short episode of dizziness without fainting im-
mediately after bicycle ergometer training. During the 
time in the rehabilitation clinic, exercise training had to 
be interrupted in 7 patients for 1–2 weeks due to respira-
tory infections, which were treated with antibiotics. All 
patients reported that they had improved their awareness 
of their physical abilities and limitations.
 Discussion 
 This is the first prospective clinical trial investigating 
the effects of respiratory and exercise training on physical 
capacity, long-term safety, time to clinical worsening and 
survival in patients with severe chronic PH and right heart 
failure. After a mean follow-up time of 24  8 12 months, 
only 1 of 58 patients had died from PH. All patients learned 
not to overdo themselves and tolerated the training well 
without severe adverse events. The cardiopulmonary ex-
ercise test has become an important clinical tool in the 
management of patients with pulmonary disease  [25–27] 
or chronic left heart failure (CHF)  [28] . Thus, exercise ca-
pacity, 6MWT, QoL, WHO functional class, heart rate at 
rest and parameters of the cardiopulmonary exercise test 
were assessed and significantly improved after 15 weeks 
compared to baseline. The results of this study indicate 
that closely supervised low-dose exercise training may 
provide a safe and powerful adjunct therapy in patients 
with severe chronic PH or at least does not seem to worsen 
the outcome. A randomized, controlled study is needed to 
investigate the long-term effect of exercise training on pa-
rameters such as QoL, exercise capacity and survival.
 The 1- and 2-year survival rates of 100 and 95%, re-
spectively, observed in the patients of the training group 
were comparable with those reported in PH patients re-
ceiving medical therapy only. In a controlled trial of an 
experienced referral center for patients with PAH class III 
or IV using an advanced therapeutic strategy including 
combinations of bosentan, sildenafil, inhaled or intrave-
nous iloprost and highly urgent lung transplantation 
when necessary, survival rates at 1, 2 and 3 years were 
93.0, 83.1 and 79.9%, respectively  [9] . Comparable 1-, 3- 
and 5-year survival rates of 92, 75 and 66%, respectively, 
have been reported in idiopathic, familial and anorexi-
gen-associated PAH  [12–14, 29] . In patients with PAH as-
sociated with systemic sclerosis, 1-, 2- and 3-year surviv-
al rates were 87, 79 and 64%, respectively  [30] .
 Using a prospective, randomized design, survival rates 
were studied in PH patients treated with intravenous epo-
prostenol  [11] . These studies also showed similar survival 
rates and a similar time to clinical worsening  [12] . In our 
study, we had no comparison to a randomized control 
group, and the main focus was to evaluate long-term safe-
ty of exercise training in this patient cohort. Therefore, 
further studies are necessary to determine the effects of 
training programs on the outcome of PH patients. How-
ever, it is a general issue of rehabilitation programs that 
the therapy cannot be performed in a blinded fashion.
 In CHF patients, several studies have suggested that 
exercise training improves time to clinical worsening and 
survival  [31, 32] . In patients with CHF due to coronary 
artery disease, total mortality was reduced by 27% fol-
lowing exercise training  [33] . The reason why exercise 
training may improve the outcome of patients with 
chronic left or right heart failure is a matter of specula-
tion. The improved functional capacity after exercise 
training may be a stimulus for a more active lifestyle that 
Table 3. S urvival and time to clinical worsening
Characteristics Training group
Patients, n 58
Follow-up for survival, months 42
Mean 8 SD 24812
Death due to PH, n 1
Lung transplantation, n 1
Hospitalization, n 1
WHO class and 6-min walking distance 
deterioration, n 3
Initiation of new chronic PH treatment, n 9
All events 15
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contributes to the maintenance of a higher peak V O 2 . Re-
cent studies in CHF have demonstrated that exercise 
training can improve neurohumoral and musculoskele-
tal abnormalities  [34] , endothelial dysfunction  [35] and 
left ventricular remodeling  [36] , and has an anti-inflam-
matory effect  [37] .
 In PH, training showed beneficial effects on right ven-
tricular function and morphology in an animal model 
 [20] and also mitochondrial and microvascular changes in 
the quadriceps muscle  [18] . The improvement in the right 
ventricular and microvascular function may be a reason 
for the beneficial effects of the training. The results of our 
study indicate that supervised respiratory and exercise 
training improves parameters which have been shown to 
be prognostically relevant in PAH patients, such as QoL 
 [16] , peak oxygen uptake  [25] and 6MWT  [15] . However, 
feasibility of this therapy has been questioned for a larger 
population of patients who have no access to local reha-
bilitation facilities  [19] . Therefore, transformation to an 
ambulatory outpatient program is warranted. Although 
no adverse events occurred during this study, we believe 
that exercise training of PH patients with right heart fail-
ure can be dangerous if it is started and performed by the 
patients themselves without a very close medical supervi-
sion. Nearly all of the patients had initially the tendency 
to overdo themselves. All patients reported that they had 
improved their awareness of their physical abilities and 
limitations within the first 3 weeks of the in-hospital su-
pervision. Especially mental training was therefore an im-
portant part of our program. Thus, there may be other 
long-term benefits of this rehabilitation program unrelat-
ed to exercise, including more frequent clinical follow-ups 
and patient education. We cannot exclude a referral bias 
since patients could apply to the training program and had 
to be clinically stable under optimized medical therapy.
 Conclusion 
 The results of this study suggest that low-dose exercise 
and respiratory training as add-on to medical therapy re-
sult in good long-term safety in a closely supervised set-
ting and may improve exercise capacity and QoL in pa-
tients with PH and right heart failure.
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